FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Fast Track for Primary Sclerosing Cholangitis Drug

[ Price : $8.95]

FDA grants HighTide Therapeutics a fast track designation for its investigational new drug, HTD1801, for treating patients with pr...

Proposed Rule on QSR Harmonization Due by 4/19: Maisel

[ Price : $8.95]

CDRH chief medical officer William Maisel reaffirms the agencys intention to modernize its Quality System regulation for medical d...

Obalon PMA Supplement OKd for Obesity Device Inflator

[ Price : $8.95]

FDA approves an Obalon Therapeutics PMA supplement for the Obalon Touch Inflation System for use in inflating the Obalon Balloon, ...

Gottlieb Touts Digital Health Approach

[ Price : $8.95]

FDA commissioner Scott Gottlieb explains the need for a new Center of Excellence for Digital Health.

FDA Proposes Special 510(k) Update, Clarification

[ Price : $8.95]

FDA solicits comments on a draft guidance to update and clarify the Special 510(k) program for some medical devices.

Additional FDA Drug Compounding Research

[ Price : $8.95]

FDA announces new and expanded research efforts into compounded drugs.

Comments Reopened on Coronary Stent Guides

[ Price : $8.95]

Federal Register notice: FDA reopens the comment period related to two draft guidance documents on coronary drug-eluting stents.

FDA Withdraws Approval for 7 ANDAs

[ Price : $8.95]

Federal Register notice: FDA withdraws approval of seven ANDAs from multiple applicants after they notified the agency in writing ...

Draft Guide on Compounding Insanitary Conditions

[ Price : $8.95]

Federal Register notice: FDA makes available a draft guidance entitled Insanitary Conditions at Compounding Facilities.

Guide on Radiopharmaceuticals from Outsourcing Facilities

[ Price : $8.95]

Federal Register notice: FDA makes available a final guidance entitled Compounding and Repackaging of Radiopharmaceuticals by Outs...